Geographic Atrophy Market Report 2024-2034

Geographic Atrophy Market Report 2024-2034

The Geographic Atrophy Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Collaborations Among Market Players are Driving the Market Growth

Rising collaborations amongst market players are driving market growth because they combine diverse expertise, resources, and technologies, accelerating the development and commercialisation of innovative treatments. Partnerships allow companies to share risks and costs associated with research and development, access each other's strengths, and enhance their competitive edge. On April 29, 2023, Astellas Pharma Inc. and Iveric Bio, Inc. announced a definitive agreement under which Astellas, through its subsidiary Berry Merger Sub, Inc.

Challenges Associated with GA Treatment Likely to Hamper Market Growth

Geographic atrophy (GA) treatment faces significant challenges, particularly in remote areas with limited healthcare access, leading to delayed detection and treatment. Raising awareness about eye health and regular exams is crucial. Current GA treatments are hindered by the lack of a cure, limited effectiveness, frequent administration, and inability to reverse damage. Advanced imaging technologies and genetic research are essential for accurate diagnosis and targeted therapies. Promising treatments, including gene and stem cell therapies, are in development, but the lack of validated endpoints and failures of late-stage drugs underscore the ongoing difficulties in treating GA.

What Questions Should You Ask before Buying a Market Research Report?

• How is the geographic atrophy market evolving?
• What is driving and restraining the geographic atrophy market?
• How will each geographic atrophy submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
• How will the market shares for each geographic atrophy submarket develop from 2024 to 2034?
• What will be the main driver for the overall market from 2024 to 2034?
• Will leading geographic atrophy markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
• Who are the leading players and what are their prospects over the forecast period?
• What are the geographic atrophy projects for these leading companies?
• How will the industry evolve during the period between 2024 and 2034? What are the implications of geographic atrophy projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the geographic atrophy market?
• Where is the geographic atrophy market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the geographic atrophy market today, and over the next 10 years:

• Our 218-page report provides 80 tables and 144 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them ‚Äì NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

Forecasts to 2034 and other analyses reveal commercial prospects

• In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising geographic atrophy prices and recent developments.

Segments Covered in the Report

Type

• Focal GA
• Multifocal GA
• Confluent GA

Drugs

• Pegcetacoplan (SYFOVRE)
• Avacincaptad pegol (IZERVAY)
• Others

Route of Administration

• Intravitreal Route
• Intravenous Route
• Others

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• E-Commerce Pharmacies

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 10 leading national markets:

North America

• U.S.
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Rest of Asia Pacific

Rest of the World (RoW)

The report also includes profiles for some of the leading companies in the Geographic Atrophy Market, 2024 to 2034, with a focus on this segment of these companies’ operations.

Leading companies profiled in the report

• Alkeus Pharmaceuticals, Inc.
• Apellis Pharmaceuticals
• Astellas Pharma Inc.
• AstraZeneca
• Bausch + Lomb
• Boehringer Ingelheim International GmbH
• F. Hoffmann-La Roche Ltd.
• Ionis Pharmaceuticals
• Johnson & Johnson
• Santen Pharmaceutical Co., Ltd.

Overall world revenue for Geographic Atrophy Market, 2024 to 2034 in terms of value the market will surpass US$4,500 million in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Geographic Atrophy Market, 2024 to 2034 report help you?

In summary, our 210+ page report provides you with the following knowledge:

• Revenue forecasts to 2034 for Geographic Atrophy Market, 2024 to 2034 Market, with forecasts for type, drugs, route of administration, and distribution channel, each forecast at a global and regional level ‚Äì discover the industry‚Äôs prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2034 for five regional and 10 key national markets ‚Äì See forecasts for the Geographic Atrophy Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, and RoW. Also forecasted is the market in the U.S., Canada, Germany, France, UK, Italy, France, Spain, China, India, and Japan among other prominent economies.
• Prospects for established firms and those seeking to enter the market ‚Äì including company profiles for 10 of the major companies involved in the Geographic Atrophy Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Geographic Atrophy Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.